OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in
point-of-care diagnostic tests, specimen collection devices, and
microbiome laboratory and analytical services, today announced that
Chronomics Limited has selected the OMNIgene®·ORAL (OME-505) saliva
collection device as a component of its SARS CoV-2 PCR test.
Chronomics Limited will supply its test for the United Kingdom’s
“Test to Release for International Travel” program. The
OMNIgene®·ORAL device is a product of OraSure’s DNA Genotek
subsidiary.
The “Test to Release for International Travel”
program enables travelers to England to purchase a COVID-19 test
privately from providers including Chronomics. Travelers who
receive a negative test result can reduce their self-isolation
period. The project is part of the UK’s plan to use Covid-19
testing to reduce the spread of the virus.
“Our selection as a supplier of oral fluid
sample collection devices by Chronomics demonstrates the broad
applicability of DNA Genotek’s technology and capabilities in
testing for, and helping to reduce the spread of, COVID-19 and
confirms DNA Genotek’s position as the leading provider of
saliva-based collection kits for detection of SARS CoV-2,” said
Kathleen Weber, Executive Vice President, Business Unit Leader,
Molecular Solutions at DNA Genotek. “If we want people to widely
adopt COVID-19 testing, a requirement to manage the current
pandemic and slowly get back to normal life, we need to make the
process painless, cost-effective, scalable and simple.”
“Our COVID-19 PCR laboratory test, using DNA
Genotek’s OMNIgene®·ORAL as the saliva collection device, is
non-invasive, easy to self-administer and the gold standard in
COVID-19 tests. We all have a responsibility to minimize the spread
of Covid-19 and our saliva test makes it far simpler to provide
customers with an easy and accurate way to test for the virus,”
said Dr. Tom Stubbs, CEO of Chronomics.
DNA Genotek’s saliva collection devices are
widely used in molecular testing to detect active COVID-19
infection. The OMNIgene®·ORAL (OME-505) collection device has
Emergency Use Authorization (EUA) from the United States Food and
Drug Administration (FDA) and is CE marked for use in the European
Union. DNA Genotek’s sample collection devices have been included
in seven customer EUAs from a range of laboratories facilitating
non-invasive collection of saliva samples for COVID-19 tests.
About OraSure Technologies
OraSure Technologies empowers the global
community to improve health and wellness by providing access to
accurate, essential information. OraSure, together with its
wholly-owned subsidiaries, DNA Genotek, Diversigen, and
Novosanis, provides its customers with end-to-end solutions
that encompass tools, services and diagnostics.
The OraSure family of companies is a leader in the
development, manufacture, and distribution of rapid diagnostic
tests, sample collection and stabilization devices, and molecular
services solutions designed to discover and detect critical medical
conditions. OraSure’s portfolio of products is sold globally to
clinical laboratories, hospitals, physician’s offices, clinics,
public health and community-based organizations, research
institutions, government agencies, pharma, commercial entities and
direct to consumers. For more information about OraSure, visit
www.orasure.com
About DNA Genotek
DNA Genotek Inc., a subsidiary of OraSure
Technologies, Inc., focuses on providing high-quality biological
sample collection products and end-to-end services for human
genomics and microbiome applications. The Company's Oragene®·Dx and
ORAcollect®·Dx product lines are the first and only FDA 510(k)
cleared saliva-based DNA collection devices for in vitro diagnostic
use. DNA Genotek also offers Research Use Only products to collect
and preserve large amounts of DNA or RNA from multiple sample
types. DNA Genotek markets its products worldwide and has a global
customer base with thousands of customers in over 100 countries.
For more information about DNA Genotek, visit
www.dnagenotek.com
About Chronomics
Founded in 2017, Chronomics, Ltd. is a UK-based
biotechnology company founded on the use of epigenetics to give
people the knowledge of how their environment and lifestyle is
imprinting itself on their DNA and affecting their health. In
response to the COVID-19 pandemic, Chronomics developed a
CE-marked, UK Government-approved saliva testing kit trusted by
thousands of people per day across Europe to detect the presence of
RNA from SARS-CoV-2 (COVID-19 virus). visit www.chronomics.com or
contact at partnerships@chronomics.com.
Proof of UK Government Approval of Chronomics:
https://www.gov.uk/government/publications/list-of-private-providers-of-coronavirus-testing/list-of-private-providers-of-coronavirus-testing
Important Information
This press release contains certain
forward-looking statements, including with respect to expected
revenues and earnings/loss per share. Forward-looking statements
are not guarantees of future performance or results. Known and
unknown factors that could cause actual performance or results to
be materially different from those expressed or implied in these
statements include, but are not limited to: ability to successfully
manage and integrate acquisitions of other companies in a manner
that complements or leverages our existing business, or otherwise
expands or enhances our portfolio of products and our end-to-end
service offerings, and the diversion of management’s attention from
our ongoing business and regular business responsibilities to
effect such integration; the expected economic benefits of
acquisitions (and increased returns for our stockholders),
including that the anticipated synergies, revenue enhancement
strategies and other benefits from the acquisitions may not be
fully realized or may take longer to realize than expected and our
actual integration costs may exceed our estimates; impact of
increased or different risks arising from the acquisition of
companies located in foreign countries; ability to market and sell
products, whether through our internal, direct sales force or third
parties; impact of significant customer concentration in the
genomics business; failure of distributors or other customers to
meet purchase forecasts, historic purchase levels or minimum
purchase requirements for our products; ability to manufacture
products in accordance with applicable specifications, performance
standards and quality requirements; ability to obtain, and timing
and cost of obtaining, necessary regulatory approvals for new
products or new indications or applications for existing products;
ability to comply with applicable regulatory requirements; ability
to effectively resolve warning letters, audit observations and
other findings or comments from the U.S. Food and Drug
Administration (“FDA”) or other regulators; the impact of the
novel coronavirus (“COVID-19”) pandemic on our business and our
ability to successfully develop new products, validate the expanded
use of existing collector products and commercialize such products
for COVID-19 testing; changes in relationships, including disputes
or disagreements, with strategic partners or other parties and
reliance on strategic partners for the performance of critical
activities under collaborative arrangements; ability to meet
increased demand for the Company’s products; impact of replacing
distributors; inventory levels at distributors and other customers;
ability of the Company to achieve its financial and strategic
objectives and continue to increase its revenues, including the
ability to expand international sales; ability to identify,
complete, integrate and realize the full benefits of future
acquisitions; impact of competitors, competing products and
technology changes; reduction or deferral of public funding
available to customers; competition from new or better technology
or lower cost products; ability to develop, commercialize and
market new products; market acceptance of oral fluid or urine
testing, collection or other products; market acceptance and uptake
of microbiome informatics, microbial genetics technology and
related analytics services; changes in market acceptance of
products based on product performance or other factors, including
changes in testing guidelines, algorithms or other recommendations
by the Centers for Disease Control and Prevention (“CDC”)
or other agencies; ability to fund research and development and
other products and operations; ability to obtain and maintain new
or existing product distribution channels; reliance on sole supply
sources for critical products and components; availability of
related products produced by third parties or products required for
use of our products; impact of contracting with
the U.S. government; impact of negative economic
conditions; ability to maintain sustained profitability; ability to
utilize net operating loss carry forwards or other deferred tax
assets; volatility of the Company’s stock price; uncertainty
relating to patent protection and potential patent infringement
claims; uncertainty and costs of litigation relating to patents and
other intellectual property; availability of licenses to patents or
other technology; ability to enter into international manufacturing
agreements; obstacles to international marketing and manufacturing
of products; ability to sell products internationally, including
the impact of changes in international funding sources and testing
algorithms; adverse movements in foreign currency exchange rates;
loss or impairment of sources of capital; ability to attract and
retain qualified personnel; exposure to product liability and other
types of litigation; changes in international, federal or state
laws and regulations; customer consolidations and inventory
practices; equipment failures and ability to obtain needed raw
materials and components; the impact of terrorist attacks and civil
unrest; and general political, business and economic conditions.
These and other factors that could affect our results are discussed
more fully in our SEC filings, including our registration
statements, Annual Report on Form 10-K for the year
ended December 31, 2019, Quarterly Report on Form 10-Q for the
quarter ended September 30, 2020, and other filings with
the SEC. Although forward-looking statements help to provide
information about future prospects, readers should keep in mind
that forward-looking statements may not be reliable. Readers are
cautioned not to place undue reliance on the forward-looking
statements. The forward-looking statements are made as of the date
of this press release and OraSure Technologies undertakes
no duty to update these statements.
Investor
Contact:
Sam
Martin
Argot
Partners
212-600-1902orasure@argotpartners.comMedia Contact:Jeanne
MellOraSure Technologies484-353-1575media@orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Sep 2023 to Sep 2024